H1 25 Results Confirm the Relevance of Roquette’s Strategy

H1 25 Results Confirm the Relevance of Roquefte’s Strategy

Lille – September 25th, 2025 - Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, today announced its 2025 H1 results, following the approval of its financial statements by the Board of Directors.

• Roquette outperforms its key markets, delivering solid H1 results in current complex market conditions.
• Successful completion of the acquisition of IFF Pharma Solutions* and implementation of a new organization with two complementary Business Groups**.
• +4% turnover growth to €2,371 million (-3% Like-For-Like basis, LFL ) and +18% EBITDA increase to €294 million (-1% LFL***), supported by a favorable mix effect and the consolidation of two months of IFF Pharma Solutions.
• +150 bps increase in EBITDA margin to 12.4% (11.2% LFL), driven by IFF Pharma Solutions and the food and nutrition segments, a consistent pricing strategy, and disciplined cost management supported by the Group’s competitiveness program. 
• Reflecting the usual seasonality of Working Capital Requirement and excluding the cash impact of the acquisition, Free Cash-Flow landed at -€150 million.

Thierry Fournier, CEO of Roquette, commented on the period: “The successful acquisition of IFF Pharma Solutions was a key milestone for the Group, leading to the evolution of our integrated operating model. With our two Business Groups, operating under the strong Roquette brand, we are already seeing positive signs of their complementarity in the H1 results.” 

 In the first half of the year, the Group outperformed its key markets:

• The Health & Pharma Solutions Business Group achieved strong results, driven by the contributions from the recently acquired IFF Pharma Solutions and the starch-based excipient business, which partially offset performance in the capsule segment. “The overall commercial results of the Business Group benefitted from the positive impact of IFF Pharma Solutions, which exceeded the Group’s forecasts. This outcome confirms the strength of Roquette’s strategy to offer a more diversified portfolio covering all drug delivery technologies, along with an expanded geographical footprint. I would add that the integration project is on track to unlock the potential of this combination as expected.”
• The Nutrition & Bioindustry Business Group’s performance was fueled by sustained demand for Roquette’s specialty products, leading to a favorable mix effect, with market share growth in some specific markets. The Business Group’s consistent pricing strategy and effective cost management led to a significant improvement in its EBITDA margin. “The Nutrition & Bioindustry Business Group has increased margins, underscoring the effectiveness of its disciplined commercial strategy. This approach has highlighted the Business Group’s ability to navigate challenging markets and contribute to overall robust results.” 

In a volatile macroeconomic environment, Roquette remains focused on the seamless execution of its strategy, its competitiveness and its deleveraging. “To effectively execute our strategy, we will focus on three key levers: operational excellence, innovation, and the implementation of our new operating model, all while continuing the successful integration of IFF Pharma Solutions in the short term. This approach is designed to enhance profitability and create value for all our stakeholders going forward,” concluded Thierry Fournier. 

* Completion of Roquette's acquisition of IFF Pharma Solutions
**  New Organization following the Acquisition of IFF Pharma Solutions
***  Like-For-Like basis excludes exchange rates impact and perimeter variation.

Press contacts

• Brunswick: Antoine Parison - +33 (0) 7 88 72 28 95 - aparison@brunswickgroup.com
• Roquette Corporate Communications: Susannah Duquesne - Susannah.duquesne@roquette.com
• Financial Communications: Eloïse de la Chaux - eloise.de-la-chaux@roquette.com